Experimental topical scabies treatment outperforms oral ivermectin in early tests

Photo by Dineshkumar Nallaveerappan via Wikimedia Commons

In an early study, an experimental topical therapy for scabies eliminated mites and eggs in a single treatment session, outperforming standard oral ivermectin.

The findings were published in Science Translational Medicine (2026 Sep; 18(869) https://doi.org/10.1126/scitranslmed.aeg5917)

In the paper, the authors note that while scabies affects roughly 400 million people annually,  current therapies lack activity against mite eggs, require repeat dosing, and are increasingly compromised by treatment failure and resistance.

“The absence of a single-application therapy capable of eliminating both motile mites and eggs represents one important limitation to effective disease control,” they say in the paper.

To try and address this therapeutic gap, investigators developed a topical therapy combining abametapir, a metalloprotease inhibitor with ovicidal activity, and flavesone, a β-triketone with rapid miticidal effects. The therapy targets multiple parasite life stages through distinct, non-neurotoxic mechanisms.

The researchers tested the topical formulation in a porcine model that closely recapitulates human scabies to assess efficacy, pruritus reduction, and pharmacologic exposure after topical administration.

In a model of severe scabies, the investigators observed that a single four-hour treatment eradicated all live mites and eggs and reduced pruritus, outperforming a standard two-dose oral ivermectin regimen. Skin pharmacokinetics demonstrated rapid attainment of concentrations with exposure profiles, supporting single-dose efficacy despite shorter systemic half-lives than ivermectin.

In their conclusions, the authors say the findings suggest the experimental therapeutic combination may offer a simplified and potentially resistance-resilient approach to scabies management.